Study: Berber calms gastrointestinal complaints through radiation therapy

Reference

li gh, Wang DL, HU YD, et al. Berber inhibits acute radiation syndrome in humans with radiation therapy in the abdomen. med oncol . 2010; 27 (3): 919-925.

Design

randomized, placebo -controlled, prospective study. Two subgroups from patients received the study medication together with standard radiation therapy during the entire study, and two subgroups received a placebo. A fifth sub -group received a placebo in the first two weeks and then the active medication.

participant

In this only article, the results of several cohorts were reported. Thirty -thirty patients with seminoms or lymphomas were treated; Half received the study medication, the rest a placebo. In addition, 42 patients were treated with cervical cancer, again half with medication and the other half with placebo. A fifth cohort was formed from 8 groups selected from both groups who should start active medication two weeks after the start of placebo treatment.

study medication and dosage

Berberin, 300 mg tablet 3 times a day

target parameter

A Radio -oncologist assessed radiation -induced toxicities such as fatigue, anorexia and nausea according to the common toxicity criteria (CTC) version 2.0.

most important knowledge

The intake of Berber reduced the frequency and severity of the radiation -induced acute intestinal syndrome in these patients compared to the patient in the control group ( p <0.05). Berber moved the symptoms so that, if they occurred later in the course of the treatment, they occurred.

effects on practice

About half of the patients in whom pelvic or abdominal cancer was diagnosed is subjected to radiation treatment. The resulting damage to the non-cancer-like tissue, especially the intestine, occurs frequently and can be serious. ^{2 Abayomi et al. reported in 2009 that of 117 women who were treated with radiation therapy due to cervical or endometrium cancer, 47 % diseased on chronic radiation entertainment. 3 Although only acute symptoms were examined in this work, we assume or hope that a reduction in acute toxicities reduces the progression to chronic inflammatory states or delayed consequences of radiation treatments can.}

This is not the first report to point out that Berber protects against radiation damage. In an article by the same authors published in August 2010, Li et al., It was also reported that Berberin protects against radiation -related intestinal damage. This earlier study was carried out on mice, not to humans. In it, mice was administered Berber and then exposed to high radiation doses. Berberin reduced the measurement of radiation damage and delayed mortality, i.e. h. It reduced the lethality of the treatment. 4

An earlier clinical study in humans in which Berberin's effect on toxicities was examined as a result of the radiation treatment of non-small cell lung cancer (NSCLC) was published in 2008. Liu et al. gave 90 patients who underwent breast radiation therapy, either Berber or placebo. The radiation of the chest causes injuries in a similar way to the radiation of the pelvis, but in this case one speaks of a radiation -induced lung damage (rili).

After 6 weeks, only 45.2 % of the patients who berber revenue, symptoms of Rili, compared to 72.1 % of the patients, had placebo. After 6 months, the numbers were 35.7 % and 65.1 %. The measurement of the lung function was also significantly better for those who took Berber.

Therefore, Berber can reduce the radiation-induced toxicity symptoms caused by radiation in the pelvic, abdominal and chest area. Does this also reduce the cytotoxicity of the treatments?